SEC Comment Letter for GT Biopharma, Inc. (GTBP) (CIK 0000109657) (GTBP) — Jul 13, 2011
GT Biopharma, Inc. (GTBP) (CIK 0000109657)
Date: July 13, 2011 · CIK: 0000109657 · Accession: 0000000000-11-042489
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-08092
Letter
July 13, 2011 Via E-mail Anthony J. Cataldo Chief Executive Officer Oxis International, Inc. 468 N. Camden Drive Beverly Hills, California 90210 Re: Oxis International, Inc. Preliminary Schedule 14A Filed July 1, 2011 File No. 000-08092
Dear Mr. Cataldo: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely,
/s/ Jeffrey Riedler Jeffrey Riedler Assistant Director
Show Raw Text
July 13, 2011 Via E-mail Anthony J. Cataldo Chief Executive Officer Oxis International, Inc. 468 N. Camden Drive Beverly Hills, California 90210 Re: Oxis International, Inc. Preliminary Schedule 14A Filed July 1, 2011 File No. 000-08092 Dear Mr. Cataldo: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jeffrey Riedler Jeffrey Riedler Assistant Director